Open label, Phase I study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and biomarker status of BAY 73-4506 in patients with advanced malignancies

Trial Profile

Open label, Phase I study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and biomarker status of BAY 73-4506 in patients with advanced malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top